Nashville Biosciences recently worked with a top-twenty pharmaceutical company to prioritize 20 early stage targets. The goal was to identify potential new therapeutic indications that fit with the company’s disease area priorities by using phenome wide association studies (pheWAS). A pheWAS-driven portfolio prioritization is only possible with a resource like BioVU® that combines a large population of prospectively genotyped subjects with a rich set of EMR-derived clinical phenotypes. Download the case study to find out how we accomplished this to help build a better drug portfolio.
Investigating genetic variants to guide neuropathic pain perception R&D
Send download link to:
Early Stage Drug Target Prioritization
Nashville Biosciences recently worked with a top-twenty pharmaceutical company to prioritize 20 early stage targets for new drug discovery or to repurpose existing drugs already in development. The goal was to identify potential new therapeutic indications that fit with the company’s disease area priorities by using phenome wide association studies (pheWAS). A pheWAS-driven portfolio prioritization is only possible with a resource like BioVU® that combines a large population of prospectively genotyped subjects with a rich set of EMR-derived clinical phenotypes. Download the case study to find out how we accomplished this to help build a better drug portfolio.
Send download link to:
